Our success as a next-generation BioPharma company will be measured by the difference we can make in the lives of patients facing serious disease. Members of the press may learn more about our company, our philanthropy and our focus on innovative medicines by viewing these resources.
At this year's ASCO and EHA meetings, we shared research across immuno-oncology, hematology and cell therapy that underscores our efforts in delivering long-term survival and improved outcomes for patients.
Our data at the 2022 American Society of Hematology (ASH) Annual Meeting reinforced our commitment to transforming the lives of patients with blood cancers and disorders through science. We shared data and research across a broad range of hematologic diseases, including multiple myeloma, lymphomas, leukemias and other blood disorders.